# Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment

> **NCT05905965** · PHASE3 · RECRUITING · sponsor: **Collegium Medicum w Bydgoszczy** · enrollment: 200 (estimated)

## Conditions studied

- Metabolic Syndrome

## Interventions

- **DRUG:** Empagliflozin 20 mg
- **DRUG:** Empagliflozin 10 mg

## Key facts

- **NCT ID:** NCT05905965
- **Lead sponsor:** Collegium Medicum w Bydgoszczy
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05905965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05905965, "Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT05905965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*